Author/Editor		Wilton, P; Boulton, J; Braemswig, J; Caruso, M; Chatelain, P; Chaussain, JL; Despert, F; Fraser, N; Frisch, H; Kržišnik, C
Title		Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome)
Type		članek
Source		Acta Paediatr Suppl
Vol. and No.		Letnik 81, št. Suppl 383
Publication year		1992
Volume		str. 137-42
Language		eng
Abstract		Twenty-seven patients (14 female, 13 male; 3 pubertal) with growth hormone receptor dificiency (Laron syndrome) were treated with recombninant insulin-like growth factor I (IGF-I), 40-120 micro g/kg body weight b.d., for up to 12 months. Height SDS was between -9.1 and -3.2 at the start of treatment (age, 3.7-22.9 xears). Before treatment, most patients had increased basal serum concentrations of growth hormone (2.4-208 mU/l) and low serum concentrations of IGF-I( less th. 20-69 micro G/l), IGF-II (69-295 micro g/l) and IGF binding protein-3 (0.16-1.59 mg/l). In all but the two oldest patients, the growth rate increased by more than 2 cm/year compared with that before treatment. Symptomatic hypoglycaemia (blood glucose less th. 3.0 mmil/l) was recorded in ten patients in 0.7 percent of measurements. Four patients experienced symptomatic hypoglycaemia. A transient asymptomatic decrease in serum potassium occurred in most patients after injections.
Descriptors		DWARFISM INSULIN-LIKE GROWTH FACTOR I SOMATOTROPIN BODY HEIGHT CHILD CLINICAL TRIALS RECEPTORS, SOMATOTROPIN HYPOGLYCEMIA BODY WEIGHT SEX FACTORS